Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival We performed a single-institution retrospective analysis of patients with R/M HNSCC treated ...
Prognostic impact of postoperative complications after neoadjuvant therapy followed by esophagectomy for esophageal cancer: An exploratory analysis of phase III trial JCOG1109.
Effectiveness of anti-epidermal growth factor receptor agents in elderly patients (age ≥ 70 years) with RAS wild-type metastatic colorectal cancer: Nationwide real-world data. This is an ASCO Meeting ...
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: Extended follow-up of a randomized controlled trial and post-treatment immune cell profiling. Nivolumab (NIVO) plus ...
Abbreviations: CR, complete response; ECOG, Eastern Cooperative Oncology Group; IFS, infantile fibrosarcoma; NOS, not otherwise specified; PD, progressive disease; PR ...
Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ≥10 months in the FRESCO-2 study. Updated analysis of ...
Impact of time to surgery on outcomes in patients with advanced esophageal squamous cell carcinoma following neoadjuvant therapy: An exploratory analysis of phase III trial JCOG1109. This is an ASCO ...
Zanidatamab dose optimization in patients with HER2-positive biliary tract cancer (BTC). Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations ...
A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable ...
Relationship in gene amplification between ERBB2 and other oncogenes: Implications for the therapeutic efficacy of trastuzumab (Tmab)-based chemotherapy (CTx) in HER2 positive gastric cancer. This is ...